Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Nanopore to Move into New Quarters Next Month, Nearly Doubling Its Space

Premium

Oxford Nanopore Technologies plans to move into new digs next month, almost doubling the space that it currently occupies.

On July 23, the nanopore DNA sequencing technology company is scheduled to move from its current location, the Begbroke Science Park just north of Oxford, where it leases 6,000 square feet, into a new building in the Oxford Science Park, about four miles southeast of Oxford.

It will occupy almost 11,000 square feet in the Edmund Cartwright Building, which will be formally opened on July 8 by Lord Drayson, the UK's minister for Science and Innovation.

"Various things have triggered the move, which … we have been planning for some time," a company spokeswoman told In Sequence last week. For example, the firm's staff has grown from 25 in early 2008 to more than 60 to date, including informaticians, scientists, and engineers. Also, "the new facility combines three floors of office and lab space within our own building, giving us room to integrate the multidisciplinary functions and also further scope to grow in the future," she said.

Oxford Nanopore has been working on commercializing a protein nanopore sequencing technology, based on research by Hagan Bayley, a professor of chemistry at Oxford (see In Sequence 2/24/2009). In January, the company received an $18 million investment from Illumina.

The Oxford Science Park, a joint venture between the University of Oxford's Magdalen College and financial services group Prudential, houses more than 60 companies, according to its website, more than 40 percent of them life science firms, and about a third computer hardware or software companies.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.